|
|
|
|
|
Ethopropazine
drug data and news
Ethopropazine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ethopropazine | ||
| Brand Names/Synonyms | Aethopropropazin; Athapropazine; Athopropazin; CHEMBANK727; Dibutil; E2880; Ethapropazine; Ethopromazine; Ethopropazine; Ethopropazine Hydrochloride; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothazine Hydrochloride; Isothiazine; Lysivane; Parcidol; Pardidol; Pardisol; Parfezin; Parfezine; Parkin; Parkisol; Parphezein; Parphezin; Parsidol; Parsidol Hydrochloride; Parsidol Monohydrochloride; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamina [Inn-Spanish]; Profenamina [Italian]; Profenamine; Profenamine Hydrochloride; Profenamine Monohydrochloride; Profenaminum; Profenaminum [Inn-Latin]; Prophenamine; Prophenaminum; RP 3356; Rochipel; Rocipel; Rodipal; SC 2538; SKF 2538; Tomil; W 483; W-483 | ||
| Indication | For use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Ethopropazine, a phenothiazine and antidyskinetic, is used in the treatment of Parkinson's disease. By improving muscle control and reducing stiffness, this drug permits more normal movements of the body as the disease symptoms are reduced. It is also used to control severe reactions to certain medicines such as reserpine, phenothiazines, chlorprothixene, thiothixene, loxapine, and haloperidol. Unlike other NMDA antagonists, ethopropazine — because of its anticholinergic action — is largely devoid of neurotoxic side effects. Ethopropazine also has a slight antihistaminic and local anesthetic effect. | ||
| Mechanism Of Action | Ethopropazine's antiparkinson action can be attributed to its anticholinergic properties. Ethopropazine partially blocks central (striatal) cholinergic receptors, thereby helping to balance cholinergic and dopaminergic activity in the basal ganglia; salivation may be decreased, and smooth muscle may be relaxed. Drug-induced extrapyramidal symptoms and those due to parkinsonism may be relieved, but tardive dyskinesia is not alleviated and may be aggravated by anticholinergic effects. Ethopropazine's local anesthetic effect is due to its antagonism of the NMDA glutamate receptor. Glutamate is recognized as an important transmitter in nociceptive pathways, and the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, in particular, has been implicated in the mediation of neuropathic pain. Excessive release of glutamate at NMDA receptors on dorsal horn neurons of the spinal cord results in hyperactivation and hypersensitivity of these receptors (perceived as hyperalgesia), thought to be an integral feature of neuropathic pain. | ||
| Ethopropazine News (When available) |
| ||
| Dosage Forms | TABLET (10 mg), SCORED TABLET (50 mg) | ||
| Drug_Category | Antiparkinson Agents; Antidyskinetics | ||
| Absorption | Well-absorbed from the gastrointestinal tract. | ||
| Interactions |
Interactions for Ethopropazine: Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects. It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action. Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine. | ||
| Toxicity | Symptoms of overdose include severe clumsiness or unsteadiness, severe drowsiness, severe dryness of mouth, nose, or throat, fast heartbeat, shortness of breath or troubled breathing, and warmth, dryness, and flushing of skin. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine | ||
| Chemical Formula | C19H24N2S | ||
| Molecular Weight | 312.473 g/mol | ||
| Smiles String | CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31 | ||
| Melting Point | 64.5 °C | ||
| Water Solubility | 0.693 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 5.772 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 1 to 2 hours | ||
| Protein Binding [%] | 93% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Ethopropazine.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00729 | ||
| CAS Registry Number | 1094-08-2 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:302402 | ||
| PharmGKB ID | PA449531 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1927744 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |